Portal de Periódicos da CAPES

Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study

2010; Oxford University Press; Volume: 66; Issue: 1 Linguagem: Inglês

10.1093/jac/dkq397

1460-2091

Gian María Rossolini, Matthew Dryden, Roman S. Kozlov, Alvaro Quintana, Robert K. Flamm, J.M. Läuffer, E. Lee, Ian Morrissey, Manfred Fille, Encho Savov, Tzvetan Velinov, Helena Žemličková, F. Ghaly, Julie Cremniter, Pierre-Yves Donnio, Jean‐Louis Fauchere, T. Fosse, Laurie Gutmann, Vincent Jarlier, P. Lannote, Hélène Marchandin, Max Maurin, José L. Pons, Claude–James Soussy, Jacques Tankovic, Marianne Abele‐Horn, Sören Gatermann, Günther, E. Jacobs, Colin R. MacKenzie, U. Mai, Reinier Mutters, W. Pfister, C. Schoerner, F.-J. Schmitz, Sabine Schubert, Harald Seifert, H. Malamou‐Lada, O. Paniara, J. Papaparaskevas, Dimitra Petropoulou, N Vakalis, E.G. Smyth, AS Moses, G. Rahav, Pierangelo Clerici, Giovanni Gesu, F. Giacomo, Antonio Goglio, M. Li Bergoli, Recker Mario, Giuseppe Nicoletti, P. Nicoletti, D. A. Repetto, Gian María Rossolini, D. L. Rubattu, Vittorio Sambri, Mario Sarti, Claudio Scarparo, Antonio Spanò, A. G. M. Buiting, SB Cohen, J.A.J.W. Kluijtmans, Johan W. Mouton, Mireille van Westreenen, Piotr B. Heczko, Waleria Hryniewicz, M. Łuczak, Anna Przondo‐Mordarska, A. Sawicka–Grzelak, M. Cristino, D. M. J. Espinar, D. M. da Graca Ribeiro, R. Koslov, D Kotulová, D. Alos, Javier Aznar, Emilio Bouza, Jhosep Blanco, Brea, Rafael Cantón, Casal, Fernando Cháves, Garcia-Rodriguez, Linares, Marco, Pascual, Picazo, Concha Gimeno, Guillem Prats, D. Revillo, Daniel Igor Amorim Carvalho dos Santos, Segovia, Perez-Trallero, J. Bille, Reto Frei, Kathrin Mühlemann, Jacques Schrenzel, Reinhard Zbinden, H. Akdeniz, Mustafa Berktaş, İsmail Balık, Serhat Birengel, BA Besirbellioglu, Ahmet Başustaoğlu, Reyhan Öztürk, Bilgül Mete, Yeşim Taşova, Filiz Kibar, Ayşe Willke Topçu, Devrim Dündar, Serhat Ünal, Deniz Gür, Onur Ural, E. Inci Tuncer, Gaye Usluer, Gül Durmaz, Ayşe Yüce, Zeynep Gülay, E. Brown, Nicholas M. Brown, Matthew Dryden, Katherine A. Gould, Achyut Guleri, M. Morgan, R. Mulla, A. Swann,

Bacterial Identification and Susceptibility Testing

To assess the in vitro activity of ceftobiprole and comparators against a recent collection of Gram-positive and Gram-negative pathogens, in order to detect potential changes in susceptibility patterns, and to evaluate the Etest assay for ceftobiprole susceptibility testing. Contemporary Gram-positive and Gram-negative isolates (excluding extended-spectrum β-lactamase-producing isolates) from across Europe and the Middle East were collected, and their susceptibility to ceftobiprole, vancomycin, teicoplanin, linezolid, ceftazidime and cefepime was assessed using the Etest method. Quality testing [using Etest and broth microdilution (BMD)] was conducted at a central reference laboratory. Some 5041 Gram-positive and 4026 Gram-negative isolates were included. Against Gram-positive isolates overall, ceftobiprole had the lowest MIC50 (0.5 mg/L), compared with 1 mg/L for its comparators (vancomycin, teicoplanin and linezolid). Against methicillin-resistant Staphylococcus aureus, all four agents had a similar MIC90 (2 mg/L), but ceftobiprole had a 4-fold better MIC90 (0.5 mg/L) against methicillin-susceptible strains. Only 38 Gram-positive isolates were confirmed as ceftobiprole resistant. Among Gram-negative strains, 86.9%, 91.7% and 95.2% were susceptible to ceftobiprole, ceftazidime and cefepime, respectively. Pseudomonas aeruginosa was less susceptible to all three antimicrobials than any other Gram-negative pathogen. There was generally good agreement between local Etest results and those obtained at the reference laboratory (for ceftobiprole: 86.8% with Gram-negatives; and 94.7% with Gram-positives), as well as between results obtained by BMD and Etest methods (for ceftobiprole: 98.2% with Gram-negatives; and 98.4% with Gram-positives). Ceftobiprole exhibits in vitro activity against a wide range of Gram-positive and Gram-negative pathogens, including multidrug-resistant strains. No changes in its known susceptibility profile were identified.